Improving hepatitis C direct-acting antiviral access and uptake: A role for patient-reported outcomes and lived experience.
Goutzamanis S, Doyle J, Higgs P, Hellard M
Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030.
Howell J, Pedrana A, Cowie BC, Doyle J, Getahun A, Ward J, Gane E, Cunningham C, Wallace J, Lee A, Malani J, Thompson A, Hellard ME
Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.
Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J, International Network on Hepatitis in Substance Users (INHSU)
Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial.
Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME
Measuring and understanding the attitudes of Australian gay and bisexual men towards biomedical HIV prevention using cross-sectional data and factor analyses.
Wilkinson AL, Draper BL, Pedrana AE, Asselin J, Holt M, Hellard ME, Stoové M
A survey of hepatitis C management by Victorian GPs after PBS-listing of direct-acting antiviral therapy.
Wade A, Draper B, Doyle J, Allard N, Grinzi P, Thompson A, Hellard M